MAXYGEN INC Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2011-11-09: Form 8-K; Period of report 2011-11-09; Description 8.01 Other Events; Details 8.01.
- 2011-11-07: Form 8-K; Period of report 2011-11-07; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2011-10-11: Form 8-K; Period of report 2011-10-10; Description 8.01 Other Events; Details 8.01.
- 2011-08-08: Form 8-K; Period of report 2011-08-08; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2011-11-09 | 8-K | 2011-11-09 | 8.01 Other Events | 8.01 On November 9, 2011, Maxygen, Inc. (the “Company”) issued a press release announcing that it has been advised by the Biomedical Advanced Research and Development Authority (BARDA) that the Company’s proposal for the development of its MAXY-G34 product candidate as a potential medical countermeasure for Acute Radiation Syndrome (ARS) will not be considered for a contract award. | d254423d8k.htm |
| 2011-11-07 | 8-K | 2011-11-07 | 2.02 Results of Operations and Financial Condition | 2.02 On November 7, 2011, Maxygen, Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2011. | d253076d8k.htm |
| 2011-10-11 | 8-K | 2011-10-10 | 8.01 Other Events | 8.01 On October 10, 2011, Maxygen, Inc. (“Maxygen”) issued a press release announcing that the United States Patent and Trademark Office (“PTO”) has issued a Right of Appeal Notice in the inter partes reexamination proceeding for U.S. Pat. | d242239d8k.htm |
| 2011-08-08 | 8-K | 2011-08-08 | 2.02 Results of Operations and Financial Condition | 2.02 On August 8, 2011, Maxygen, Inc. issued a press release announcing its financial results for the three and six months ended June 30, 2011. | d8k.htm |
| 2011-05-31 | 8-K | 2011-05-27 | 5.07 Submission of Matters to a Vote of Security Holders; 8.01 Other Events | 5.07 Maxygen, Inc. (the “Company”) held its Annual Meeting of Stockholders on May 27, 2011. 8.01 On May 31, 2011, the Company issued a press release announcing a $10.0 million stock repurchase program. | d8k.htm |
| 2011-05-20 | 8-K | 2011-05-16 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 1.01 Entry into a Material Definitive Agreement. 1.02 Effective upon the Closing Date, the various agreements among Maxygen, Perseid, Astellas and Astellas Bio that governed the relationship between the parties as joint venture partners and investors in Perseid, including the master joint venture agreement, the investors’ rights agreement, the co-sale agreement and the voting agreement automatically terminated. 2.01 The information set forth in Item 1.01 is incorporated by reference into this Item 2.01. 5.02 Effective as of the Closing Date, Mr. Yonehiro, the President and Chief Executive Officer of Perseid, will no longer serve as an executive officer of Maxygen. | d8k.htm |
| 2011-05-05 | 8-K | 2011-05-05 | 2.02 Results of Operations and Financial Condition | 2.02 On May 5, 2011, Maxygen, Inc. issued a press release announcing its financial results for the three months ended March 31, 2011. | d8k.htm |
| 2011-03-17 | 8-K | 2011-03-16 | 8.01 Other Events | 8.01 On March 16, 2011, Astellas Pharma Inc. (“Astellas”) exercised its option to purchase all of the equity interests of Maxygen, Inc. (“Maxygen”) in Perseid Therapeutics LLC (“Perseid”) at the current exercise price of $76.0 million. | d8k.htm |
| 2011-03-08 | 8-K | 2011-03-08 | 2.02 Results of Operations and Financial Condition | 2.02 On March 8, 2011, Maxygen, Inc. issued a press release announcing its financial results for the quarter and year ended December 31, 2010. | d8k.htm |
| 2011-01-31 | 8-K | 2011-01-31 | 8.01 Other Events | 8.01 On January 31, 2011, Maxygen, Inc. (“Maxygen”) issued a press release regarding the initiation of a Phase I clinical study to evaluate a next-generation CTLA4-Ig therapeutic (designated as ASP2408) that is being developed by Perseid Therapeutics LLC, Maxygen’s majority-owned subsidiary, in collaboration with Astellas Pharma Inc. for the treatment of rheumatoid arthritis and potentially other autoimmune indications. | d8k.htm |